Stock price movements

Merck (MRK) closed at $78.19 on May 10, 0.18% below its previous close, 36.01% above its 52-week low of $57.49, and 6.75% below its 52-week high of $83.85. The company’s market capitalization was $204.55 billion, and its PE, forward PE, PEG (PE-to-growth), PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios were 33.60x, 14.92x, 3.38x, 4.84x, 7.66x, and 23.08x, respectively.

Merck’s 14-day RSI (relative strength index) score is 48.06. It has 2.62 billion outstanding shares and a short float ratio of 0.86%.

AbbVie (ABBV) closed at $77.45 on May 10, 0.59% below its previous close, 2.22% above its 52-week low of $75.77, and 27.79% below its 52-week high of $107.25. The company’s market capitalization was $114.70 billion, and its PE, forward PE, PEG, PS, and PC ratios were 21.85x, 8.20x, 2.86x, 3.51x, and 14.23x, respectively. AbbVie’s 14-day RSI score is 38.80. It has 1.48 billion outstanding shares and a short float ratio of 1.87%.

What Analysts Recommend for MRK and ABBV StockReady to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Analysts’ recommendations and target price

Most analysts covering Merck recommend “buy,” and most covering AbbVie recommend “hold.” Their 12-month target price for Merck stock rose from $84.02 in February to $85.52 in March, $86.79 in April, and $88.07 in May, which implies a 12.64% upside based on the stock’s May 10 closing price. Of the 17 analysts covering Merck, six recommend “strong buy,” eight recommend “buy,” and three recommend “hold.”

Analysts’ 12-month target price for Abbvie was reduced from $93 in February to $92.18 in March and April, and $89.73 in May, which implies a 15.86% upside based on the stock’s May 10 closing price. Of the 17 analysts covering AbbVie, one recommends “strong buy,” three recommend “buy,” 11 recommend “hold,” one recommends “sell,” and one recommends “strong sell.”

Latest articles

Last week (ended August 16) was rough for Canopy Growth (WEED)(CGC) stock. It fell about 14% after the company's fiscal 2020 first-quarter earnings report.

Apple shares rose close to 3% in early hour trading on Monday. So, why is Apple stock trading higher? The market sentiment might have turned positive.

Huawei plans to launch its own mapping service as soon as this October. But Huawei’s Map Kit will initially not be a consumer mapping service.

In April, Amazon announced its plan to transform its free two-day shipping program to a free one-day shipping program for its Prime customers.

Cannabis companies face regulatory challenges. Recently, CannTrust (CTST) didn't comply with Health Canada’s regulations.

China’s state media agency, Xinhua News Agency, reported on August 18 that police had seized a FedEx parcel containing a handgun.